Nabriva Therapeutics plc (NBRVF) Stock Price, Quote & News - Stock Analysis (2024)

FAQs

Is Nabriva Therapeutics going out of business? ›

Nabriva Therapeutics says it is going to wind down, becoming the latest antibiotic developer to fail commercially. Nabriva was formed in 2006 from Sandoz's antibiotic research operations.

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections.

Even after a failed phase 3 pediatric clinical trial, Applied Therapeutics forged ahead with an FDA filing for potential market approval. Now the regulatory agency has extended the review period for the rare disease prospect, pushing back a possible decision date into November and sending the biotech's stock tumbling.

In the letter, the FDA asked for additional safety and efficacy data before Galera files for resubmission. The news about the letter and layoffs led to the drop in Galera's stock by about 85%.

Both formulations of lefamulin were granted Qualified Infectious Disease Product and Fast Track designation by the FDA. On August 19, 2019, the FDA Approved Xenleta^®(lefamulin) for both Oral and IV use.

Nabriva owns exclusive, worldwide rights to lefamulin. We intend to further pursue the development of this antibiotic and are developing a formulation that is also appropriate for pediatric use.

Lefamulin belongs to the class of medicines known as pleuromutilin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections.

XENLETA® is a pleuromutilin antimicrobial agent discovered and developed by Nabriva Therapeutics plc (Head Office: Dublin, Ireland; “Nabriva Therapeutics”).

Drug sales are anticipated to have high growth, primarily driven by COVID-19 therapeutics, the continued adoption of many new and innovative therapies, a favorable M&A environment, and a low prevalence of patent expirations in 2022.

Is Plus Therapeutics a buy? ›

What do analysts say about Plus Therapeutics Inc? Plus Therapeutics Inc's analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.